论文部分内容阅读
目的 探究PCF和DCF两种化疗方案治疗进展期胃癌的疗效及副作用.方法 回顾性分析2010年1月—2014年1月就诊的进展期胃癌患者45例的病历资料,根据化疗方案不同分为研究组(n=25)和对照组(n=20),研究组采用PCF(紫杉醇脂质体+氟尿嘧啶+奥沙利铂)方案;对照组采用DCF(多西他赛+氟尿嘧啶+奥沙利铂)方案.对比两组患者化疗的疗效及副作用.结果 研究组的总有效率为72.0%,对照组为65.0%,差异无统计学意义(P>0.05).研究组化疗后生活质量增加的比例(40.0%)高于对照组(15.0%),差异有统计学意义(P<0.05).研究组Ⅲ度消化道反应(4.0%)和Ⅲ度骨髓抑制的比例(28.0%)低于对照组(25.0%和55.0%),差异均有统计学意义(P<0.05).研究组2年生存率(84.0%)高于对照组(60.0%),差异有统计学意义(P0.05). The proportion of life quality increasing of research group (40.0%) was higher than that of control group (15.0%) (P<0.05). The proportions of degree Ⅲ digestive tract reaction and degree Ⅲ myelosuppression of research group (4.0%, 28.0%) were lower than those of control group (25.0%, 55.0%) (P<0.05). The 2 year survival rate of research group (84.0%) was higher than that of control group (60.0%) (P<0.05). Conclusion As for patients with advanced gastric cancer, the effect of PCF and DCF chemotherapy regimens is equivalent, but side effects is small, and of the former it is worthy of clinical promotion.